GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (FRA:36X) » Definitions » Price-to-Free-Cash-Flow

Ascentage Pharma Group International (FRA:36X) Price-to-Free-Cash-Flow : N/A (As of May. 07, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International Price-to-Free-Cash-Flow?

As of today (2025-05-07), Ascentage Pharma Group International's share price is €5.65. Ascentage Pharma Group International's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.06. Hence, Ascentage Pharma Group International's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Ascentage Pharma Group International's Price-to-Free-Cash-Flow or its related term are showing as below:

FRA:36X's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 28.965
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Ascentage Pharma Group International's Free Cash Flow per Share for the six months ended in Dec. 2024 was €0.10. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €-0.06.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 54.30% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 32.00% per year.

During the past 9 years, Ascentage Pharma Group International's highest 3-Year average Free Cash Flow per Share Growth Rate was 54.30% per year. The lowest was -168.40% per year. And the median was -18.55% per year.


Ascentage Pharma Group International Price-to-Free-Cash-Flow Historical Data

The historical data trend for Ascentage Pharma Group International's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International Price-to-Free-Cash-Flow Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only - - - - -

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ascentage Pharma Group International's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Ascentage Pharma Group International's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascentage Pharma Group International's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's Price-to-Free-Cash-Flow falls into.


;
;

Ascentage Pharma Group International Price-to-Free-Cash-Flow Calculation

Ascentage Pharma Group International's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=5.65/-0.061
=N/A

Ascentage Pharma Group International's Share Price of today is €5.65.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascentage Pharma Group International's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Ascentage Pharma Group International  (FRA:36X) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Ascentage Pharma Group International Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascentage Pharma Group International Business Description

Address
68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

Ascentage Pharma Group International Headlines

No Headlines